Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
73.26
-1.64 (-2.19%)
At close: Mar 6, 2026, 4:00 PM EST
73.00
-0.26 (-0.35%)
After-hours: Mar 6, 2026, 6:14 PM EST
Tarsus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 451.36 | 182.95 | 17.45 | 25.82 | 57.03 | Upgrade
|
| Revenue Growth (YoY) | 146.71% | 948.62% | -32.42% | -54.73% | - | Upgrade
|
| Cost of Revenue | 95.01 | 66.21 | 51.91 | 43.58 | 43.79 | Upgrade
|
| Gross Profit | 356.35 | 116.74 | -34.46 | -17.76 | 13.24 | Upgrade
|
| Selling, General & Admin | 427.32 | 237.31 | 108.7 | 44.95 | 25.4 | Upgrade
|
| Operating Expenses | 427.32 | 237.31 | 108.7 | 44.95 | 25.4 | Upgrade
|
| Operating Income | -70.97 | -120.57 | -143.16 | -62.71 | -12.16 | Upgrade
|
| Interest Expense | -8.94 | -7.85 | -3.35 | -2.2 | - | Upgrade
|
| Interest & Investment Income | 15.75 | 15.01 | 10.34 | 3.5 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.2 | 0.39 | 0.02 | 0.09 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -64.36 | -113.02 | -136.15 | -61.33 | -12.12 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.59 | 0.26 | -0.77 | -1.58 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.07 | Upgrade
|
| Other Unusual Items | - | -1.94 | - | - | - | Upgrade
|
| Pretax Income | -64.36 | -115.55 | -135.89 | -62.1 | -13.77 | Upgrade
|
| Income Tax Expense | 2.06 | - | - | -0 | 0.06 | Upgrade
|
| Net Income | -66.42 | -115.55 | -135.89 | -62.09 | -13.83 | Upgrade
|
| Net Income to Common | -66.42 | -115.55 | -135.89 | -62.09 | -13.83 | Upgrade
|
| Shares Outstanding (Basic) | 42 | 38 | 29 | 25 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 38 | 29 | 25 | 21 | Upgrade
|
| Shares Change (YoY) | 11.11% | 27.98% | 19.35% | 19.78% | 231.12% | Upgrade
|
| EPS (Basic) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | Upgrade
|
| EPS (Diluted) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | Upgrade
|
| Free Cash Flow | -22.31 | -84.59 | -119 | -49.54 | 3.16 | Upgrade
|
| Free Cash Flow Per Share | -0.53 | -2.25 | -4.05 | -2.01 | 0.15 | Upgrade
|
| Gross Margin | 78.95% | 63.81% | -197.50% | -68.81% | 23.22% | Upgrade
|
| Operating Margin | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% | Upgrade
|
| Profit Margin | -14.71% | -63.16% | -778.89% | -240.51% | -24.25% | Upgrade
|
| Free Cash Flow Margin | -4.94% | -46.24% | -682.04% | -191.88% | 5.54% | Upgrade
|
| EBITDA | -69.15 | -119.34 | -142.28 | -62.39 | -11.85 | Upgrade
|
| EBITDA Margin | -15.32% | -65.23% | - | -241.66% | -20.77% | Upgrade
|
| D&A For EBITDA | 1.82 | 1.23 | 0.88 | 0.33 | 0.31 | Upgrade
|
| EBIT | -70.97 | -120.57 | -143.16 | -62.71 | -12.16 | Upgrade
|
| EBIT Margin | -15.72% | -65.90% | - | -242.92% | -21.32% | Upgrade
|
| Revenue as Reported | 451.36 | 182.95 | 17.45 | 25.82 | 57.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.